A sign is posted in front of the 23andMe headquarters in Sunnyvale, Calif., on Feb. 1, 2024. Genetic testing company 23andMe, once valued at $6 billion, is facing the possibility of delisting from NASDAQ as the company navigates numerous class action lawsuits. Justin Sullivan/Getty ImageByAldgra Fredly
0 Comments